Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders.

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companies work together to innovate around the discovery, development, and manufacturing of new drugs.

DiCicco gives an update on TransCelerate’s work with pragmatic trials and the group’s meetings last year with the FDA. He discusses what pragmatic trials are and how they can improve the efficiency of clinical research, as well as describing the work that was done at the meeting last year and the report that’s come out of it.

He also gets into next steps, how the new administration has and hasn’t affected the work TransCelerate is doing with the FDA, and the role TransCelerate plays in taking these recommendation and putting them into practice.

Tune in to learn how the pharma industry is working together to change the way clinical trials are done.